Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of NTAL protein interactors

ABSTRACT: The adaptor protein NTAL (non-T cell activation linker) is expresses in acute myeloid leukemia blasts, and its downregulation by alkylphospholipid treatment or protein expression knockdown reduces AKT activation. This new data elucidates new NTAL protein interactions.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Suspension Culture, Leukocyte

DISEASE(S): Acute Leukemia

SUBMITTER: Vitor Faca

LAB HEAD: Vitor Marcel Faça

PROVIDER: PXD005850 | Pride | 2021-09-10

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

The Expression of NTAL and Its Protein Interactors Is Associated With Clinical Outcomes in Acute Myeloid Leukemia.

Thomé Carolina Hassibe CH Ferreira Germano Aguiar GA Pereira-Martins Diego Antonio DA Augusto Dos Santos Guilherme G Almeida-Silveira Douglas R DR Weinhäuser Isabel I Antônio de Souza Gustavo G Houtsma Roos R Schuringa Jan Jacob JJ Rego Eduardo M EM Faça Vitor M VM

Molecular & cellular proteomics : MCP 20210507

Non-T cell activation linker (NTAL) membrane protein depletion from lipid rafts by alkylphospholipids or downregulation by shRNA knockdown decreases cell viability through regulation of the Akt/PI3K pathway in mantle cell lymphoma and acute promyelocytic leukemia cells. Here, we confirmed that the knockdown of NTAL in acute myeloid leukemia (AML) cell lines was associated with decreased cell proliferation and survival. Similarly, a xenograft model using AML cells transduced with NTAL-shRNA and t ...[more]

PMID: 33971369

Similar Datasets

BRD9 regulates leukemic cell survival via STAT5 pathway inhibition

Project description:Leukemia is characterized by genetic and epigenetic mutations resulting in selection of cancer stem cells, which are unable to differentiate. While genetic alterations are difficult to target, the epigenome is intrinsically dynamic and readily offers new therapeutic strategies. Thus, identifying cancer-specific context-dependent targets and unraveling their biological function may open up new therapeutic perspectives. Here, we identify bromodomain-containing protein 9 (BRD9) as a critical target required in acute myeloid leukemia (AML). We show that BRD9 is overexpressed in AML cells including ex vivo primary blasts compared to CD34+. By targeting BRD9 expression in AML, we observed an alteration in proliferation and survival, ultimately resulting in the induction of apoptosis. Intriguingly, genome-wide profiling revealed that BRD9 binds enhancer regions in a cell type-specific manner, regulating cell type-related processes. We unveil a novel BRD9-sustained STAT5 pathway activation via regulation of SOC3 expression levels. Our findings identify a previously undescribed BRD9-STAT5 axis as critical for leukemia maintenance, suggesting BRD9 as a potential therapeutic target.

2019-11-11 | PXD013245 | Pride

Model-driven analysis of metabolic immunomodulators of macrophage activation

Project description:Model-driven multi-omic data analysis of the RAW 264.7 cell line elucidates metabolic immunomodulators of macrophage activation

2015-11-11 | PXD003055 | Pride

Epigenetically Induced Ectopic Expression of UNCX in Acute Myeloid Leukemia Associated with Impaired Proliferation and Differentiation of Myeloid Cells

Project description:We performed gene-expression profiling (GEP) of UNCX-positive versus UNCX-negative AML patients using exon-array and gene-pathway analyses. UNCX is a homeobox gene ectopically expressed in acute myeloid leukemia (AML) patients and cell lines, whose activation is induced by epigenetic modifications. Our results showed a novel leukemogenic role of UNCX in slowing myeloid cell proliferation with a differentiation arrest in AML blasts. Accordingly, UNCX expression characterizes AML cells at early stage of differentiation, mainly M2 and M3 FAB types carrying wild-type NPM1. Overall, our findings provide new relevant insights into the role of epigenetically activated homeobox genes in leukemogenesis, defining a new subgroup of AML patients.

2016-11-01 | E-MTAB-4098 | biostudies-arrayexpress

The Proteome and Transcriptome of Stress Granules and P-Bodies during Human T Lymphocytes Activation

Project description:Stress granules (SGs) and processing bodies (PBs) are membraneless cytoplasmic assemblies regulating mRNAs under environmental stress such as viral infections, neurological disorders, or cancer. Upon antigen stimulation, T lymphocytes mediate their immune functions under regulatory mechanisms involving SGs and PBs. However, the impact of T cell activation on such complexes, in term of formation, constitution and relationship remains unknown. Here, by combining proteomic, transcriptomic and immunofluorescence approaches, we simultaneously characterized the SGs and PBs from primary human T lymphocytes pre- and post-stimulation. The proteomes and transcriptomes of SGs and PBs were identified, unveiling an unanticipated molecular and functional complementarity. Notwithstanding, these granules keep distinct spatial organizations and abilities to interact with mRNAs. This comprehensive characterization of the RNP granule proteomic and transcriptomic landscapes provides a unique resource for future investigations on SGs and PBs in T lymphocytes.

2023-03-10 | PXD031639 | Pride

Mus musculus

Project description:Model-driven multi-omic data analysis elucidates metabolic immunomodulators of macrophage activation

| PRJNA171843 | ENA

O-GlcNAcylation and chaperonin CCT5 protect OTX2 from aggregation in medulloblastoma cellsO-GlcNAcylation andanalysis of OTX2 O-GlcNac sites and dependent interactions

Project description:In this study, we demonstrated that OTX2 was transcriptionally and post-transcriptionally regulated by O-GlcNAcylation. We describe the modes of degradation of this essential homeobox protein involving both the proteasome and macroautophagy. While the proteasome remains the canonical degradation pathway, we demonstrated that OTX2 forms oligomers and/or aggregates that are resistant to proteasomal degradation and require macroautophagy. Furthermore, elevated cellular concentration of OTX2 promoted aggregation, OTX2 could either interact with the chaperonin CCT5 or be O-GlcNAcylated at the key residues (S1135/S136/T137) to prevent its oligomerization, suggesting a protective role of O-GlcNAcylation in OTX2 turnover.

2024-01-22 | PXD040353 | Pride

Human AML secretome and exosomes and correlation with Anti-Apoptotic Index, part 3

Project description:Expression of proteins regulating apoptosis (BCL-2, MCL-1, BCL-X and BAX) in acute myeloid leukemia (AML) blasts at diagnosis have been shown to be associated with disease-free survival. We previously found that the initially high apoptosis-resistance of AML cells decreased after therapy, while regaining high levels at relapse. This suggested a dynamic regulation of apoptosis. We hypothesized that expression of apoptosis-related proteins in AML blasts, and possibly also in bystander cells in the bone marrow, is regulated by extracellular factors present in the AML microenvironment. Tumor cell communication with its microenvironment is emerging as an important determinant playing multiple roles in cancer. Both soluble factors and extracellular vesicles (EVs), most notably exosomes, have been shown to influence cellular processes of malignant and normal cells in the tumor microenvironment. We performed a proteomics analysis of the whole secretome as well as of EVs secreted by AML blasts to pinpoint released protein factors that might mediate apoptosis-resistance.

2016-02-03 | PXD001487 | Pride

Human AML secretome and exosomes and correlation with Anti-Apoptotic Index, part 4

Project description:Expression of proteins regulating apoptosis (BCL-2, MCL-1, BCL-X and BAX) in acute myeloid leukemia (AML) blasts at diagnosis have been shown to be associated with disease-free survival. The concentrations of these proteins are combined in the Anti Apoptotic index (AAI). We previously found that the initially high apoptosis-resistance of AML cells decreased after therapy, while regaining high levels at relapse. This suggested a dynamic regulation of apoptosis. We hypothesized that expression of apoptosis-related proteins in AML blasts, and possibly also in bystander cells in the bone marrow, is regulated by extracellular factors present in the AML microenvironment. Tumor cell communication with its microenvironment is emerging as an important determinant playing multiple roles in cancer. Both soluble factors and extracellular vesicles (EVs), most notably exosomes, have been shown to influence cellular processes of malignant and normal cells in the tumor microenvironment. We performed a proteomics analysis of the whole secretome as well as of EVs secreted by AML blasts to pinpoint released protein factors that might mediate apoptosis-resistance.

2016-02-03 | PXD003478 | Pride

Transcriptome analysis of blast Side and Main populations cells in patients with acute myeloid leukemia

Project description:Acute myeloid leukemia (AML) represent a series of hemopathies characterized by the clonal expansion in bone marrow and blood of immature myeloid cells blocked in differentiation, called blasts. Despite significant supportive care progresses, few medical discoveries radically changed LAM prognosis (5 year survival rate of 30%). An aggressive conventional chemotherapy is used to kill AML cells. However, many patients relapse mainly due to the persistence of rare AML cells able to re-initiate the disease. Quiescence and protection against environmental stresses (chemoresistance) are major characteristics of these cells. Drug efflux leading to chemoresistance is observed by Side Population (SP) detection through ABC transporter activation. So, AML blasts presenting SP functionality could represent a chemoresistant population. This SP phenotype is essentially acquired by circulating AML blasts after contact with medullar mesenchymal stromal cells (MSC). A transcriptome analysis of AML blasts sorted according to their SP functionality or not (Non SP cells or Main Population, ie MP) after co-culture on MSCs was realized.

2020-01-18 | GSE114633 | GEO

A lysosome-targeted DNA nanodevice selectively targets macrophages to attenuate tumors

Project description:Activating CD8+ T cells by antigen cross-presentation is remarkably effective at eliminating tumors. Although this function is traditionally attributed to dendritic cells, tumor-associated macrophages (TAMs) can also cross-present antigens. TAMs are the most abundant tumor-infiltrating leukocyte. Yet, TAMs have not been leveraged to activate CD8+ T cells because mechanisms that modulate their ability to cross-present antigens are incompletely understood. Here we show that TAMs harbor hyperactive cysteine protease activity in their lysosomes which impedes antigen cross-presentation, thereby preventing CD8+ T cell activation. We developed a DNA nanodevice (E64-DNA) targeted to lysosomes of TAMs in mice. E64-DNA inhibits the population of cysteine proteases present specifically inside lysosomes of TAMs, improves their ability to cross-present antigens, and attenuates tumor growth via CD8+ T cells. When combined with cyclophosphamide, E64-DNA showed sustained tumor regression in a triple-negative-breast-cancer model. Our studies demonstrate that DNA nanodevices can be targeted with organelle-level precision to reprogram macrophages and achieve immunomodulation in vivo.

2021-10-14 | PXD028037 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data